Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Raymond Siu Ming, Navarro-Cabrera, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gómez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Savage, Jessica, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241857/
https://www.ncbi.nlm.nih.gov/pubmed/36848639
http://dx.doi.org/10.1182/bloodadvances.2022009129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241857/
https://www.ncbi.nlm.nih.gov/pubmed/36848639
http://dx.doi.org/10.1182/bloodadvances.2022009129

Ejemplares similares